Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
2(50.0%)
N/A
2(50.0%)
4Total
Phase 2(2)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06685848Not ApplicableRecruiting

Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion

Role: lead

NCT06743113Not ApplicableNot Yet Recruiting

Hypoxic Red Blood Cells in Sickle Cell Anemia

Role: lead

NCT07055503Enrolling By Invitation

Use of the Hemanext One® Hypoxic Red Blood Cell Storage System for Transfusion in Thalassemia Patients

Role: collaborator

NCT05549232Completed

Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital

Role: lead

NCT04418934Phase 2Withdrawn

Clinical Investigation to Evaluate the Hemanext® Red Blood Cell Processing System for Extended Storage of Leukoreduced Red Blood Cells

Role: lead

NCT03301779Phase 2Completed

Clinical Investigation to Evaluate the Hemanext® Oxygen Reduction System - Pivotal Trial

Role: lead

All 6 trials loaded